Alvarez-Sanchez N, Dunn S
Curr Top Behav Neurosci. 2022; 62:333-373.
PMID: 35467295
DOI: 10.1007/7854_2022_324.
Wennink R, de Boer J, Hiddingh S, Haasnoot A, Ayuso V, de Hoop T
Invest Ophthalmol Vis Sci. 2021; 62(9):19.
PMID: 34254975
PMC: 8287043.
DOI: 10.1167/iovs.62.9.19.
Mancini I, Giacomini E, Pontiggia S, Artoni A, Ferrari B, Pappalardo E
J Clin Med. 2020; 9(10).
PMID: 33096882
PMC: 7589625.
DOI: 10.3390/jcm9103379.
Yoosefinejad A, Motealleh A, Khademi S, Hosseini S
Int J MS Care. 2020; 19(2):100-104.
PMID: 32607068
PMC: 7313410.
DOI: 10.7224/1537-2073.2015-064.
Treeful A, Rendahl A, Friedenberg S
Immunogenetics. 2019; 71(5-6):373-382.
PMID: 30968193
DOI: 10.1007/s00251-019-01113-0.
The immunogenetics of neurological disease.
Misra M, Damotte V, Hollenbach J
Immunology. 2017; 153(4):399-414.
PMID: 29159928
PMC: 5838423.
DOI: 10.1111/imm.12869.
Linking Genotype to Clinical Phenotype in Multiple Sclerosis: In Search of the Holy Grail.
Longbrake E, Hafler D
JAMA Neurol. 2016; 73(7):777-8.
PMID: 27244583
PMC: 5198230.
DOI: 10.1001/jamaneurol.2016.1227.
Association of HLA Genetic Risk Burden With Disease Phenotypes in Multiple Sclerosis.
Isobe N, Keshavan A, Gourraud P, Zhu A, Datta E, Schlaeger R
JAMA Neurol. 2016; 73(7):795-802.
PMID: 27244296
PMC: 5081075.
DOI: 10.1001/jamaneurol.2016.0980.
Multiple sclerosis in men: management considerations.
Bove R, McHenry A, Hellwig K, Houtchens M, Razaz N, Smyth P
J Neurol. 2016; 263(7):1263-73.
PMID: 26725085
DOI: 10.1007/s00415-015-8005-z.
The immunogenetics of multiple sclerosis: A comprehensive review.
Hollenbach J, Oksenberg J
J Autoimmun. 2015; 64:13-25.
PMID: 26142251
PMC: 4687745.
DOI: 10.1016/j.jaut.2015.06.010.
Subcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study.
Patti F, Morra V, Amato M, Trojano M, Bastianello S, Tola M
PLoS One. 2013; 8(8):e74111.
PMID: 24137499
PMC: 3796707.
DOI: 10.1371/journal.pone.0074111.
Oligoclonal bands and age at onset correlate with genetic risk score in multiple sclerosis.
Harbo H, Isobe N, Berg-Hansen P, Bos S, Caillier S, Gustavsen M
Mult Scler. 2013; 20(6):660-8.
PMID: 24099750
PMC: 4066985.
DOI: 10.1177/1352458513506503.
Sex and gender issues in multiple sclerosis.
Harbo H, Gold R, Tintore M
Ther Adv Neurol Disord. 2013; 6(4):237-48.
PMID: 23858327
PMC: 3707353.
DOI: 10.1177/1756285613488434.
Mortality in patients with multiple sclerosis.
Scalfari A, Knappertz V, Cutter G, Goodin D, Ashton R, Ebers G
Neurology. 2013; 81(2):184-92.
PMID: 23836941
PMC: 3770174.
DOI: 10.1212/WNL.0b013e31829a3388.
Progress in multiple sclerosis genetics.
Goris A, Pauwels I, Dubois B
Curr Genomics. 2013; 13(8):646-63.
PMID: 23730204
PMC: 3492804.
DOI: 10.2174/138920212803759695.
Environmental factors associated with disease progression after the first demyelinating event: results from the multi-center SET study.
Horakova D, Zivadinov R, Weinstock-Guttman B, Havrdova E, Qu J, Tamano-Blanco M
PLoS One. 2013; 8(1):e53996.
PMID: 23320113
PMC: 3540021.
DOI: 10.1371/journal.pone.0053996.
The genetics of multiple sclerosis: an up-to-date review.
Gourraud P, Harbo H, Hauser S, Baranzini S
Immunol Rev. 2012; 248(1):87-103.
PMID: 22725956
PMC: 5967887.
DOI: 10.1111/j.1600-065X.2012.01134.x.
Multiple sclerosis susceptibility-associated SNPs do not influence disease severity measures in a cohort of Australian MS patients.
Jensen C, Stankovich J, van der Walt A, Bahlo M, Taylor B, van der Mei I
PLoS One. 2010; 5(4):e10003.
PMID: 20368992
PMC: 2848851.
DOI: 10.1371/journal.pone.0010003.
Environmental factors and their timing in adult-onset multiple sclerosis.
Handel A, Giovannoni G, Ebers G, Ramagopalan S
Nat Rev Neurol. 2010; 6(3):156-66.
PMID: 20157307
DOI: 10.1038/nrneurol.2010.1.
Modification of Multiple Sclerosis Phenotypes by African Ancestry at HLA.
Cree B, Reich D, Khan O, De Jager P, Nakashima I, Takahashi T
Arch Neurol. 2009; 66(2):226-33.
PMID: 19204159
PMC: 4334456.
DOI: 10.1001/archneurol.2008.541.